THE HOT SNARE

A new cycle in the academic year is nearly upon us. Follow this link to learn about the newest members of our team.

From the Director’s Desk:

Article of the Week:

Suggested Reading:

From the editors of Gastroenterology:

Armstrong, A et al, Gastroenterology 2023; 164:228 – 240 Unfermented beta-fructan fibers fuel inflammation in select inflammatory bowel disease patients

Mukherjee, P et al Gastroenterology 2023; 165:1180 – 1196 Stricturing Crohn’s disease single- cell RNA sequencing reveals fibroblast heterogeneity and intracellular interactions

Yarur, A et al Gastroenterology 2023; 165:963 – 975 Higher intra-abdominal visceral adipose tissue mass is associated with lower rates of clinical and endoscopic remission in patients with inflammatory bowel diseases initiating biologic therapy: results of the constellations study

Garay, J et al Gastroenterology 2023; 165:870 – 681 Microbiota composition is associated with future onset of Crohn’s disease in healthy first-degree relatives

Livianos, A et al Gastroenterology 2023; 164:619 – 629 Anti-integrin alpha-v-beta autoantibodies are a novel biomarker that antedate ulcerative colitis

From the editors of American Journal of Gastroenterology:

Mortreux P, et al, American Journal Gastroenterology, 2023; 118(9) : 1671 – 1678 Natural history of renal ulcerations in pediatric- onset CD

Johnson A et al, American Journal Gastroenterology 2023; 118(2): 317 – 328 Real-world effectiveness and safety of Ustekinumab

Seishima.R et al, American Journal Gastroenterology 2023; 118(7): 1248 – 1255 Biologics are not associated with advanced stage CRC

Bachour SP, et al American Journal Gastroenterology 2023. Anastomotic configuration does not influence anastomotic stricture formation

From the European Journals:

Agrawal, M,et al, Gastroenterology. 2023; 165(4): 976 – 985 Early ileocecal resection for Crohn’s disease is associated with improved long-term outcomes compared with antitumor necrosis factor therapy: a population-based cohort study

Van Linschoten, R, etal, Lancet Gastroenterol hepatology. 2023; 8(4): 343 – 355 Increased versus conventional adalimumab dose interval for patients with Crohn’s disease in stable remission(LAD): a pragmatic open label, noninferiority, randomized controlled trial

Louis, E et al, Lancet Gastroenterology hepatology 2023; eight(3): 215 – 227 Withdrawal of infliximab or con comment immunosuppressant therapy in patients with Crohn’s disease on combination therapy(SPARE): a multi-center, open labeled, randomized controlled trial

Meimo-van Praag et al, E clinical medicine 2023; 61: 102-0454 Short term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn’s disease(PISA-11): a patient preference randomized trial

Travis, S et al New England Journal of Medicine 2023; 388(13): 1191 – 1200 Vedolizumab for the treatment of chronic pouchitis

From the Surgical Journals:

Spinelli, A et al, Colorectal disease 2021; 23:2690 – 2698 Patient’s perceptions of surgery for inflammatory bowel disease

Luglio, G et al Annals of surgery volume 272 number 2 August 2020 Surgical prevention of anastomotic recurrence by excluding mesentery in Crohn’s disease: the SuPREMe-CD Study-a randomized clinical trial

Dozois, E et al, Diseases of the colon and rectum 2023; 66:243 – 252 durable response in patients with refractory fistulizing perianal Crohn’s disease using autologous mesenchymal stem cells on a dissolvable matrix: results from the phase 1 stem cell on matrix plug trial

Aydlinli, h et al, Diseases of the colon and rectum 2020; 63:1102-1107 Trans abdominal pouch salvage for failed minimally invasive is versus open I PAA: a case matched study

A Review of Available Medical Therapies to Treat Moderate -to-Severe Inflammatory Bowel Disease, American Journal of Gastroenterology, vol 119, January 2024, 55-80

Living in Cincinnati

Mission Statement & Recruitment Procedures

Introduction to the GI Faculty